Business Insights

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges.

One solution for these challenges is to engage HCPs – virtually.

Spotlight

FSC Pediatrics

FSC Pediatrics, Inc. was founded in 2004 to address significant unmet needs faced by pediatricians and their patients. FSC Pediatrics markets and distributes pediatric-friendly pharmaceutical products and medical devices that have been approved for children.

OTHER WHITEPAPERS
news image

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More
news image

Simulation in the pharmaceutical industry

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

Read More

Spotlight

FSC Pediatrics

FSC Pediatrics, Inc. was founded in 2004 to address significant unmet needs faced by pediatricians and their patients. FSC Pediatrics markets and distributes pediatric-friendly pharmaceutical products and medical devices that have been approved for children.

Events